trending Market Intelligence /marketintelligence/en/news-insights/trending/uTAz3fphD-kjTHd02fHQtw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

CTI BioPharma prices $45M preferred stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


CTI BioPharma prices $45M preferred stock offering

CTI BioPharma Corp. priced an underwritten public offering of 22,500 series N-3 preferred stock at $2,000 apiece to raise $45 million in gross proceeds.

The company had originally planned to issue the stock at $1,000 apiece. The stocks are convertible into common shares of the company at a rate of $3 apiece for a total of about 15 million common shares.

CTI plans to use the net proceeds to conduct its PAC203 clinical trial, submit a new marketing authorization application for pacritinib with the European Medicines Agency, conduct research for the possible application of pacritinib in indications other than myelofibrosis and complete its PIX306 clinical trial.

Jefferies LLC is acting as the sole book-running manager for the offering, while BTIG LLC is acting as its lead manager.

The offering is expected to close by June 9.